The impact of early PEG-asparaginase discontinuation in young adults with ALL: a post hoc analysis of the CALGB 10403 study
- Citation:
- Blood Adv vol 7 (2) 196-204
- Year:
- 2022
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Secondary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- collection
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Book Volume:
- 12
- Parents:
- None
- Children:
- None
- Pharmas:
- Enzon Pharmaceuticals
- Grants:
- U10CA180821, U10CA180882, P30CA033572, UG1CA232760, UG1CA233253, UG1CA233290, UG1CA233327, UG1CA233328, UG1CA233331, UG1CA233373
- Corr. Author:
- Authors:
- Ibrahim Aldoss Jun Yin Anna Wall Krzysztof Mrózek Michaela Liedtke David F. Claxton Matthew C. Foster Frederick R. Appelbaum Harry P. Erba Mark R. Litzow Martin S. Tallman Richard M. Stone Richard A. Larson Anjali S. Advani Wendy Stock Selina M. Luger
- Networks:
- CA043, LAPS-IL036, LAPS-IL057, LAPS-MA036, LAPS-MN026, LAPS-NC007, LAPS-NC010, LAPS-OH007, OH027
- Study
- CALGB-10403
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2
- Keywords:
- Clinical Trials and Observations